Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.34 |
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | STAT1 | P42224 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023543 | 0.84 | KMT2A (0.62) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL2023579 | 0.81 | MEN1 (0.46) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL3419583 | 0.79 | MEN1 (0.39) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL2971654 | 0.79 | MEN1 (0.45) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL2650764 | 0.78 | MEN1 (0.44) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL11764046 | 0.78 | ALDH1A1 (0.44) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL1020567 | 0.77 | MEN1 (0.67) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL5046716 | 0.77 | DHODH (0.58) | MEN1KMT2AMAPTKDM4ENPSR1 | |
| SCHEMBL395325 | 0.76 | DHODH (0.46) | MAPTKDM4ENPSR1DHODHGAA | |
| SCHEMBL10782206 | 0.76 | MAPT (0.63) | KMT2AMAPTKDM4ENPSR1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314590-A1 | Substituted quinolones and methods of use | ChemoCentryx, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1954274-B8 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1954274-B1 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1954274-A4 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1954274-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | MEN1 1755/4885KMT2A 1633/4885MAPT 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.